SMS Pharmaceuticals Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript SMS Pharmaceuticals Ltd filed with BSE on 30 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
SMS Pharmaceuticals reported 13% revenue growth to INR887 crores and EBITDA margin expansion to 20% for FY26, with PAT rising 47% to INR102 crores including a contribution from associate VKT Pharma. Management attributed the improvement to backward integration in ibuprofen, favorable product mix and operating leverage, while noting the anti-diabetic segment was deprioritized in favor of ARV and anti-inflammatory APIs. For FY27, management guided to 15% revenue growth and further margin improvement from the FY26 level of 20%, citing geopolitical uncertainty affecting logistics and raw material costs.
Numbers mentioned
Revenue: INR238 crores (Q4 FY26)
p. 3
“Revenue for Q4 FY26 stood at INR238 crores.”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
Revenue: INR887 crores (FY26)
p. 3
“For the full year, revenue increased by 13% to INR887 crores, supported by strong growth across our anti-inflammatory and ARV segment.”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
Gross profit: INR81 crores (Q4 FY26)
p. 3
“Gross profit for Q4 stood at INR81 crores.”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
Gross profit: INR303 crores, up 14% (FY26)
p. 3
“For FY26, gross profit increased 14% to INR303 crores, while gross margins remained healthy at 34%.”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
EBITDA: INR40 crores, margin 17% (Q4 FY26)
p. 3
“EBITDA in Q4 was INR40 crores with margins at 17%.”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
EBITDA: INR171 crores, up 23%, margin 20% (FY26)
p. 3
“For the full year, EBITDA stood at INR171 crores, up 23% with margins improving to 20%, reflecting the benefits of backward integration, favorable product mix and operating leverage.”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
PAT: INR33 crores (Q4 FY26)
p. 3
“In Q4 FY26, PAT was INR33 crores, including a INR12 crores contribution from our associate company, VKT Pharma.”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
PAT: INR102 crores, up 47% (FY26)
p. 3
“For FY26 PAT rose 47% to INR102 crores supported by margin”
Vamsi Krishna Potluri, page 3 of the filed PDF · View the filing
PAT including VKT share: INR88 crores, up 28% (FY26)
p. 4
“Extending our share of VKT Pharma's profit, PAT grew 28% to INR88 crores compared to INR67 crores in FY25.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
DMF and CEP filings: 12 (FY26)
p. 4
“we filed 12 DMFs and CEPS during FY26 and intend to maintain this pace with 10 additional filings targeted in FY27 and further 10 filings planned for FY28.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
Brownfield project investment: INR130 crores of planned INR280 crores
p. 4
“Against the total planned investment of approximately INR280 crores, we have already invested around INR130 crores.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
Ibuprofen capacity: 500 tons per month currently, 80% utilized
p. 5
“We are currently sitting at 500 tons per month capacity.”
Vamsi Krishna Potluri, page 5 of the filed PDF · View the filing
Ibuprofen share of revenue: around 20%
p. 9
“Roughly around 20%. It is roughly around 20%.”
Vamsi Krishna Potluri, page 9 of the filed PDF · View the filing
Export share of revenue: 70%
p. 7
“I think 70% will be exports for us.”
Vamsi Krishna Potluri, page 7 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Installed capacity — 800 metric tons per month · FY27
stated firmly by Vamsi Krishna Potluri
p. 4
“Upon completion of our current capex program in FY27, our installed capacity will increase to 800 metric tons per month.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
Revenue growth — 15% · FY27
stated conditionally by Vamsi Krishna Potluri
p. 5
“Taking these factors into account, we are guiding for 15% revenue growth while aiming to further improve upon our FY26 EBITDA margin of 20%.”
Vamsi Krishna Potluri, page 5 of the filed PDF · View the filing
Revenue growth — exceed current guidance · FY27
stated conditionally by Vamsi Krishna Potluri
p. 5
“At the same time, if the external environment stabilizes and logistics conditions improve, we believe there is potential for growth to exceed our current guidance given the opportunities we see for our products.”
Vamsi Krishna Potluri, page 5 of the filed PDF · View the filing
EBITDA margin — 22% · next year
stated as an aspiration by Vamsi Krishna Potluri
p. 6
“But next year, we are trying to reach 22%.”
Vamsi Krishna Potluri, page 6 of the filed PDF · View the filing
Revenue growth (medium term) — 20% to 25% · FY28, FY29
stated as an aspiration by Vamsi Krishna Potluri
p. 8
“So definitely, see our target is to hit at least 20% to 25%. That is our actual target.”
Vamsi Krishna Potluri, page 8 of the filed PDF · View the filing
High value product share — around 60%
stated as an aspiration by Vamsi Krishna Potluri
p. 7
“Probably around like 60%.”
Vamsi Krishna Potluri, page 7 of the filed PDF · View the filing
Brownfield expansion revenue contribution — FY28 with further scale-up in FY29
stated firmly by Vamsi Krishna Potluri
p. 4
“We expect these products to begin contributing meaningfully during FY28 with further scale-up expected in FY29.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
Peptides commercial roadmap update — next 2 quarters
stated firmly by Vamsi Krishna Potluri
p. 4
“Currently, we are working on multiple products, and we will give greater clarity on the commercial road map after the next 2 quarters.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
CDMO initiative update — next 2 quarters
stated firmly by Vamsi Krishna Potluri
p. 4
“The project is progressing well, and we expect to be in a better position to provide a more comprehensive update after the next 2 quarters.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
Capex commissioning and incremental revenue — FY27 completion, FY28 revenue
stated firmly by Vamsi Krishna Potluri
p. 6
“So, this will be completed by FY27, March, and the capex will be completed, and we expect incremental revenues from FY28.”
Vamsi Krishna Potluri, page 6 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said it was due to higher raw material costs from a rise in solvent prices in March linked to the war.
Answered by Vamsi Krishna Potluri
Asked by Vihaan Bagri: What caused the quarter-on-quarter decline in gross margin?
p. 5
“This is mainly due to increase of raw material consumption. And this is due to increase in solvent cost in March.”
Vamsi Krishna Potluri, page 5 of the filed PDF · View the filing
One project expands ibuprofen backward integration capacity to 800 metric tons per month; the other is a brownfield block for new high-margin APIs.
Answered by Vamsi Krishna Potluri
Asked by Vihaan Bagri: What is the breakup and timeline of the capex projects?
p. 5
“We are currently sitting at 500 tons per month capacity. Now we are increasing our capacity to 800 metric tons”
Vamsi Krishna Potluri, page 5 of the filed PDF · View the filing
Management said backward integration in ibuprofen was the main driver, helping the company remain competitive amid price escalation.
Answered by Vamsi Krishna Potluri
Asked by Maitri Shah: What is driving the targeted EBITDA margin increase to 22%?
p. 6
“So the main reason that we are able to sustain the EBITDA margins this year is because of our strong backward integration.”
Vamsi Krishna Potluri, page 6 of the filed PDF · View the filing
Management said exports were around 70% and expected to grow slightly to 70-75%.
Answered by Vamsi Krishna Potluri
Asked by Maitri Shah: What is the export percentage of revenue and will it change with new APIs?
p. 8
“Yes, it will be around that range, growth of maybe 4%, 5%, yes. I think it will be around 70%, 75%.”
Vamsi Krishna Potluri, page 8 of the filed PDF · View the filing
Management confirmed intent to strengthen it further.
Answered by Lakshmi Narayana
Asked by Bhavani Prasad Kulkarni: Is the company planning to increase OCF conversion ratio further?
p. 8
“Obviously, we plan to further strengthen the OCF conversion ratio.”
Lakshmi Narayana, page 8 of the filed PDF · View the filing
Management said the 28% comes from multiple products with that single customer, not one product.
Answered by Vamsi Krishna Potluri
Asked by Bhavani Prasad Kulkarni: Does the 28% revenue concentration from the largest customer represent a concentration risk?
p. 9
“Single customer, but it is from multiple products. It is not a single product contribution.”
Vamsi Krishna Potluri, page 9 of the filed PDF · View the filing
Management explained VKT buys APIs from SMS, and SMS buys intermediates from SMS Life Sciences, a separately promoted entity.
Answered by Vamsi Krishna Potluri
Asked by Jaiprakash: What is the rationale for related-party transactions with VKT Pharma and SMS Life Sciences?
p. 9
“But the promoters -- see it's been coming under the related party because the promoters have some investment in SMS Life Sciences.”
Vamsi Krishna Potluri, page 9 of the filed PDF · View the filing
Management said there are no such plans currently as these are separately run companies in a different category.
Answered by Vamsi Krishna Potluri
Asked by Jaiprakash: Is there any plan to bring VKT Pharma or SMS Life Sciences into the SMS Pharma fold?
p. 9
“At this point of time, no, it's again, as I told you, SMS Life Sciences is a separately run -- it's an independent company.”
Vamsi Krishna Potluri, page 9 of the filed PDF · View the filing
Risks flagged
Geopolitical developments in the Middle East creating uncertainty in logistics, freight and supply chain stability
p. 5
“Ongoing geopolitical developments in the Middle East have introduced uncertainties around logistics, freight movements and supply chain stability for both raw materials and finished products.”
Vamsi Krishna Potluri, page 5 of the filed PDF · View the filing
Rising solvent costs due to war increasing raw material costs
p. 5
“So because of the war, the solvent costs have increased drastically, and that resulted in increase of raw material cost for the product.”
Vamsi Krishna Potluri, page 5 of the filed PDF · View the filing
Evolving pricing and demand environment in the anti-diabetic segment
p. 4
“Anticipating the evolving pricing and demand environment, we proactively adjusted our strategy at the beginning of Q3 FY26 before the impact became visible.”
Vamsi Krishna Potluri, page 4 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.